Michigan House Bill HB4878

Michigan 2025-2026 Regular Session

• Introduced: 9/11/25
• Refer: 9/11/25

Caption

Health: pharmaceuticals; reporting certain information and regulating certain conduct related to drugs and the federal 340B program; provide for. Creates new act.

Impact

The bill is poised to impact state laws significantly by enforcing stricter compliance requirements for entities involved in the 340B program. Hospitals will be compelled to ensure that any savings accrued under this program are reinvested into patient care or bestowed upon community benefit programs. Furthermore, manufacturers and wholesalers are prohibited from taking actions that could restrict the access of 340B entities to necessary drugs, potentially leveling the playing field for hospitals serving lower-income populations.

Summary

House Bill 4878 introduces comprehensive measures regarding the federal 340B drug pricing program, aiming to enhance transparency and accountability among pharmaceutical manufacturers and healthcare providers. The bill mandates hospitals participating in the 340B program to report specific information concerning drug acquisition costs, payments received, and community investments. This information must be submitted annually, facilitating oversight of how savings from the program are utilized to benefit patient services and community health initiatives.

Contention

Notable points of contention surrounding HB 4878 could arise from the implications of increased regulatory oversight and reporting burdens on both healthcare providers and pharmaceutical manufacturers. Critics may argue that the bill could lead to increased operational costs for hospitals as they adapt to new compliance standards, particularly concerning extensive reporting obligations. Moreover, some manufacturers might view the stipulations as an infringement on their business practices, leading to a pushback against perceived overreach by state regulatory authorities.